Financials • AtaiBeckley

ATAI

Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
12/2019	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2020	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2021	20	-136	-123	L	L	377	L	-362	-	-127	-1	410	-128	0	0	-	-
12/2022	0	-145	-123	L	L	261	L	-258	-	-147	-1	21	-148	0	0	-	-
12/2023	0	-125	-12	L	L	243	L	-161	-	-117	-1	-8	-118	0	0	-	-
12/2024	0	-102	0	1,800%	0.03	116	5%	-45	-	-108	-0	5	-108	0	0	-	-
12/2025	4	-643	-1	L	L	222	L	-256	-	-117	-1	269	-118	0	0	-	-

To see all financials—including updated, you must be Premium.